We use privacy-friendly analytics. Read our privacy policy.

Scientific Literacy

How to Read Scientific Studies

Scientific interpretation involves evaluating evidence quality, study design, population size, effect estimates, uncertainty, limitations, reproducibility, mechanistic plausibility, and clinical relevance.

Educational neuropharmacology and ethnobotanical interpretation should remain cautious, evidence aware, and transparent about uncertainty and what a study can—and cannot—establish.

Evidence strength review

Evidence: Stronger

Human trials and clinical relevance

Well-designed human trials can provide direct evidence about outcomes in the populations studied. Systematic reviews and meta-analyses can add broader context when the included studies are sufficiently comparable and trustworthy.

Research limitations

Randomization does not erase every limitation. Sample-size adequacy, missing data, outcome selection, follow-up duration, adherence, selective reporting, conflicts of interest, and applicability to other populations still matter.

Evidence strength review

Evidence: Moderate

Mechanistic evidence

Mechanistic studies can help explain receptor systems, signaling pathways, metabolism, and biological plausibility.

Research limitations

A plausible mechanism does not by itself establish a meaningful benefit, an effective dose, or long-term safety in humans.

Referenced Research

Research references

PubMed Research Database

NIH / PubMed

Office of Dietary Supplements

NIH ODS

NCCIH Research Resources

NCCIH

Evidence Interpretation

Research limitations

  • Single studies should rarely be interpreted in isolation.
  • Animal and cell models may clarify mechanisms but do not establish human efficacy.
  • Many herbal interventions still lack large, long-duration, independently replicated human trials.
  • Publication bias, selective reporting, and conflicts of interest can affect the available evidence base.

Questions to ask before trusting a result

Was the sample size justified? A participant count is not good or bad by itself. Power depends on the expected effect, outcome variability, design, attrition, and statistical plan.

Was the comparison fair? Randomization, an appropriate comparator, allocation procedures, and blinding can reduce important biases when they are feasible. Lack of blinding raises concern most when outcomes or decisions are vulnerable to expectations.

What outcome was actually measured? A change in a biomarker or intermediate endpoint is not automatically the same as a patient-important benefit. Surrogate outcomes need evidence that they reliably predict the outcome they are standing in for.

How precise and reproducible is the effect? Look beyond the p-value. Check the effect size, confidence interval, missing data, pre-specified outcomes, replication, and consistency with the broader literature.

Who funded the study? Funding does not automatically invalidate a trial, but conflicts of interest and sponsor involvement deserve scrutiny. Large reviews have found industry-sponsored drug and device studies more often report favorable efficacy results and conclusions than non-industry-sponsored studies.

Is the follow-up long enough for the claim? A short trial can answer a short-term question. It generally cannot establish durability or uncommon long-term harms.

Source ledger

References

4 sources

  1. 01
    Greenhalgh T. (2014). How to Read a Paper, 5th ed. BMJ Books.
  2. 02
    Ioannidis JPA. (2005). Why most published research findings are false. PLoS Med, 2(8): e124.
  3. 03
    Lundh A, et al. (2018). Industry sponsorship and research outcome: systematic review with meta-analysis. Intensive Care Med, 44(10):1603-1612.
  4. 04
    Manyara AM, et al. (2023). Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate end points in trials: a scoping review. J Clin Epidemiol, 160:83-99.